Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in Uveitis (ENDURE Extension)
NCT01090310Phase 3Terminated
- Sponsor
- Novartis
- Start
- Aug 2010
- Primary completion
- Jul 2011
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 3 trial of secukinumab in noninfectious uveitis (NIU), sponsored by Novartis. Started Aug 2010; status: terminated.
02
Drugs
secukinumab
03
Conditions
noninfectious uveitis (NIU)
Beyond the preview
Go deeper on NCT01090310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01090310.